Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial.
Authors
James, NSydes, M
Mason, M
Clarke, Noel W
Anderson, J
Dearnaley, D
Dwyer, J
Jovic, G
Ritchie, A
Russell, J
Sanders, K
Thalmann, G
Bertelli, G
Birtle, A
O'Sullivan, J
Protheroe, A
Sheehan, D
Srihari, N
Parmar, M
Affiliation
School of Cancer Sciences, University of Birmingham, Birmingham, UK.Issue Date
2012-05
Metadata
Show full item recordAbstract
Long-term hormone therapy alone is standard care for metastatic or high-risk, non-metastatic prostate cancer. STAMPEDE--an international, open-label, randomised controlled trial--uses a novel multiarm, multistage design to assess whether the early additional use of one or two drugs (docetaxel, zoledronic acid, celecoxib, zoledronic acid and docetaxel, or zoledronic acid and celecoxib) improves survival in men starting first-line, long-term hormone therapy. Here, we report the preplanned, second intermediate analysis comparing hormone therapy plus celecoxib (arm D) with hormone therapy alone (control arm A).Citation
Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. 2012, 13 (5):549-58 Lancet OncolJournal
Lancet OncologyDOI
10.1016/S1470-2045(12)70088-8PubMed ID
22452894Type
ArticleLanguage
enISSN
1474-5488ae974a485f413a2113503eed53cd6c53
10.1016/S1470-2045(12)70088-8